Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis.
IBD
flexible sigmoidoscopy
infliximab
ulcerative colitis
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
29
03
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Guidelines recommend performing a flexible sigmoidoscopy in patients hospitalized with acute severe ulcerative colitis (ASUC). However, it is unclear if time to sigmoidoscopy affects relevant clinical outcomes. We aimed to assess the impact of early sigmoidoscopy on clinical outcomes using a well-characterized cohort of patients with ASUC. This is a single-center, retrospective study of all patients hospitalized with ASUC from January 1, 2012 to November 1, 2021. Early sigmoidoscopy was defined as occurring within 72 hours of admission while delayed sigmoidoscopy was defined as occurring >72 hours after admission. Primary outcomes were cumulative days of intravenous (IV) corticosteroid (CS) use, length of hospital stay, and colectomy rates. Secondary outcomes were time to infliximab (IFX) rescue and inpatient opioid medication use. A total of 112 patients hospitalized with ASUC who underwent sigmoidoscopy were included in the analysis. Eighty-seven patients (78%) had early sigmoidoscopy and 25 (22%) had delayed sigmoidoscopy. Patients in the early sigmoidoscopy group were exposed to significantly fewer days of IV CS (4.5 vs 9.2 days; In this well-characterized cohort, early sigmoidoscopy in ASUC was associated with favorable clinical outcomes. These findings highlight the benefits of early sigmoidoscopy in patients with ASUC. Larger prospective studies are needed to corroborate these findings.
Identifiants
pubmed: 37323477
doi: 10.1093/crocol/otad032
pii: otad032
pmc: PMC10263117
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otad032Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Déclaration de conflit d'intérêts
B.A.-B.: Speaker honoraria: AbbVie, Takeda. Advisory board: Bristol Meyers Squibb. J.K.J.G.: AbbVie Speaker Bureau. D.D.P.: AbbVie consulting. All other authors have no financial disclosures or conflicts of interest.
Références
Aliment Pharmacol Ther. 2016 Jul;44(2):127-44
pubmed: 27226344
Dig Liver Dis. 2008 Oct;40(10):821-6
pubmed: 18472316
Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751
pubmed: 29562277
J Crohns Colitis. 2010 Oct;4(4):431-7
pubmed: 21122540
Dig Dis Sci. 2013 Feb;58(2):519-25
pubmed: 22926499
Clin Gastroenterol Hepatol. 2021 May;19(5):895-907.e4
pubmed: 32835841
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2269-2278.e3
pubmed: 31887450
J Crohns Colitis. 2015 May;9(5):376-81
pubmed: 25770163
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Inflamm Bowel Dis. 2019 Nov 14;25(12):1990-1995
pubmed: 31087042
J Clin Gastroenterol. 2021 Sep 1;55(8):709-715
pubmed: 32804686
Clin Transl Gastroenterol. 2016 Dec 1;7(12):e203
pubmed: 27906164
Br Med J. 1955 Oct 29;2(4947):1041-8
pubmed: 13260656
J Clin Gastroenterol. 2019 Feb;53(2):127-133
pubmed: 29206751
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2031-2045.e11
pubmed: 33127595
J Crohns Colitis. 2013 May;7(4):322-37
pubmed: 23395397
Scand J Gastroenterol. 2023 Mar;58(3):232-239
pubmed: 36073852
Am J Gastroenterol. 2012 Feb;107(2):179-94; author reply 195
pubmed: 22108451
Aliment Pharmacol Ther. 2000 Mar;14(3):273-9
pubmed: 10735919
Clin Gastroenterol Hepatol. 2020 May;18(6):1252-1260
pubmed: 32007542
Aliment Pharmacol Ther. 2013 May;37(10):953-62
pubmed: 23550660
Crohns Colitis 360. 2021 Dec 05;3(4):otab080
pubmed: 36777265
J Crohns Colitis. 2019 Feb 1;13(2):144-164
pubmed: 30137275
Aliment Pharmacol Ther. 2021 Mar;53(6):704-711
pubmed: 33497484
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3
pubmed: 28625817
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Gastroenterology. 2008 Dec;135(6):1907-13
pubmed: 18854185
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):815-24
pubmed: 25262931
World J Gastroenterol. 2017 Jul 21;23(27):4986-5003
pubmed: 28785153